A novel peptidomimetic therapeutic for selective suppression of lung cancer stem cells over non-stem cancer cells

Shukla, Satya Prakash; Raymond, Aaron; Rustagi, Vineeta; Kedika, Samanth R.; Tran, Olivia N.; Wang, Liye; Guo, Bin; Udugamasooriya, D. Gomika

doi:10.1016/j.bioorg.2021.105340

Cited by 7 publications

(3 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, Shukla et al ( 2021 ), identified a peptidomimetic with unique characteristics (called PCS2D1.2) that specifically targets the cancer stem cells (CSC) subpopulation of lung cancer on residual cancer cells (non-CSCs). Unlike PCS2 peptoid, which did not exhibit anticancer activity, PCS2D1.2 shows high anti-cancer potency.…”

Section: Peptiodomemtics Against Metastasismentioning

confidence: 99%

See 1 more Smart Citation

Peptidomimetics in cancer targeting

Gomari

Abkhiz

Pour

et al. 2022

Mol Med

View full text Add to dashboard Cite

The low efficiency of treatment strategies is one of the main obstacles to developing cancer inhibitors. Up to now, various classes of therapeutics have been developed to inhibit cancer progression. Peptides due to their small size and easy production compared to proteins are highly regarded in designing cancer vaccines and oncogenic pathway inhibitors. Although peptides seem to be a suitable therapeutic option, their short lifespan, instability, and low binding affinity for their target have not been widely applicable against malignant tumors. Given the peptides’ disadvantages, a new class of agents called peptidomimetic has been introduced. With advances in physical chemistry and biochemistry, as well as increased knowledge about biomolecule structures, it is now possible to chemically modify peptides to develop efficient peptidomimetics. In recent years, numerous studies have been performed to the evaluation of the effectiveness of peptidomimetics in inhibiting metastasis, angiogenesis, and cancerous cell growth. Here, we offer a comprehensive review of designed peptidomimetics to diagnose and treat cancer.

show abstract

Section: Peptiodomemtics Against Metastasismentioning

confidence: 99%

“…According to the results of this investigation on the H358 cell line (lung cancer), PCS2D1.2 significantly inhibited cell metastasis by inhibiting known markers of CSC ALDH1A3, SOX2, and pectin. PCS2D1.2 specifically affects CSCs, while does not affect non-CSCs (Shukla et al 2021 ).…”

Section: Peptiodomemtics Against Metastasismentioning

confidence: 99%

Peptidomimetics in cancer targeting

Gomari

Abkhiz

Pour

et al. 2022

Mol Med

View full text Add to dashboard Cite

show abstract

“…The activity of ALDH (aldehyde dehydrogenase) in lung cancer, especially in drug-tolerant persister (DTP) cells, is a candidate biomarker for CSCs and has been increasingly identified as playing important roles in cancer aggressiveness and drug resistance [9]. Plectin appears on the cell surface as a novel marker of CSCs, and targeting it would effectively reduce plectin expression and plectin + CSCs, but had no effect on non-CSCs [10 ▪▪ ]. Additionally, multiple markers instead of only a single marker are considered the screening program for identifying lung CSCs.…”

Section: Identification and Characteristics Of Lung Cancer Stem Cellsmentioning

confidence: 99%

Targeting cancer stem cell pathways for lung cancer therapy

Liu

2022

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewThe unique properties of cancer stem cells (CSCs) make lung cancer untargetable for quite an extended period. The functional mechanism of this cell type has been illustrated step by step. However, the outcomes of lung cancer patients are still lower than expected clinically. The attempts made by scientists to make challenge history against stemness maintenance of lung cancer cells and their druggable targets are worth elucidating. Recent findingsMany agents, including the Bispecific T-cell engager (BiTE) and AMG 119 targeting DLL3-positive cells, are a tremendous breakthrough in the preclinical and clinical treatment of SCLC. More studies focus on targeting CSCs to overcome TKI resistance in NSCLC. The combo targeting of CSC and the immune microenvironment can favor the treatment of lung cancer patients.

show abstract

Optimization of a cell surface vimentin binding peptoid to extract antagonist effect on lung cancer cells

Zhang

Udugamasooriya

2022

Bioorganic Chemistry

View full text Add to dashboard Cite

A novel peptidomimetic therapeutic for selective suppression of lung cancer stem cells over non-stem cancer cells

Cited by 7 publications

References 63 publications

Peptidomimetics in cancer targeting

Peptidomimetics in cancer targeting

Targeting cancer stem cell pathways for lung cancer therapy

Optimization of a cell surface vimentin binding peptoid to extract antagonist effect on lung cancer cells

Contact Info

Product

Resources

About